# Endocannabinoid System Research and Clinical Psychosis Care > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/clinical-psychosis-care-endocannabinoid-system-research/ > **Published:** 2026-04-22T23:35:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:00:22-04:00 > **Clinical Summary:** Explore clinical psychosis care through endocannabinoid system research to improve early psychosis treatment and reduce legal involvement. --- #### Clinical Takeaway Clinical Takeaway People experiencing first-episode psychosis have measurable rates of criminal legal involvement that can be identified at baseline and tracked over treatment. Understanding which clinical and demographic factors predict legal involvement during early psychosis may help clinicians implement targeted interventions to reduce this outcome. ### #13 Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis. **Citation:** Scanlon Faith et al. *Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis.* The Journal of clinical psychiatry. 2026. PMID: 41920015. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Psychosis  |  **CED Score:** 11 Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Abstract:** Objective: Because limited research has evaluated criminal legal involvement (CLI) during a first episode of psychosis (FEP), we explored rates, correlates, and predictors of CLI among people with FEP. Methods: We conducted a secondary analysis on the Recovery After an Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) study, a cluster randomized controlled trial conducted from 2010 to 2012 with people experiencing FEP in the US. We explored rates of recent CLI prior to baseline and over the 2-year follow-up and evaluated predictors of CLI at baseline and over the follow-up period (N = 381). Results: At baseline, 11% of the sample reported CLI within the past month, which was significantly associated with lower education, longer duration of untreated psychosis, lifetime alcohol or any drug use disorder (other than cannabis), and more severe excitement factor symptoms on the Positive and Negative Syndrome Scale (PANSS). Over the 2-year follow-up, 13.6% of the sample reported CLI which, controlling for baseline CLI, was predicted by longer duration of untreated psychosis, schizophrenia diagnosis, lifetime alcohol or any other drug use disorder, alcohol or [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in the 30 days prior to baseline, and more severe positive and excitement symptoms on the PANSS at baseline. Those with CLI at baseline were nearly 3 times more likely to have subsequent CLI over the follow-up. Baseline CLI was associated with dropping out of treatment due to incarceration. Conclusion: The findings suggest that CLI in people with FEP could be reduced by earlier detection and more effective treatment of psychotic symptoms, substance use, and criminogenic risk factors. Trial Registration: Data used in this secondary analysis are from ClinicalTrials.gov identifier: NCT01321177.  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41920015/)[DOI ↗](https://doi.org/10.4088/JCP.25m15991) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Research: First-Episode Psychosis](https://cedclinic.com/first-episode-psychosis-predictors-endocannabinoid-system/) Explore detailed research on the endocannabinoid system's role in first-episode psychosis and its clinical implications. [Read More](https://cedclinic.com/first-episode-psychosis-predictors-endocannabinoid-system/) [Endocannabinoid System & Psychosis Risk: Clinical Evidence](https://cedclinic.com/endocannabinoid-system-psychosis-risk/) Review [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) linking the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) to psychosis risk and potential therapeutic approaches. [Explore Insights](https://cedclinic.com/endocannabinoid-system-psychosis-risk/) [Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis.](https://cedclinic.com/criminal-legal-involvement-first-episode-psychosis/) Understand factors predicting criminal legal involvement in first-episode psychosis to inform clinical care strategies. [Learn More](https://cedclinic.com/criminal-legal-involvement-first-episode-psychosis/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20Research%20and%20Clinical%20Psychosis%20Care&url=https%3A%2F%2Fcedclinic.com%2Fclinical-psychosis-care-endocannabinoid-system-research%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fclinical-psychosis-care-endocannabinoid-system-research%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20Research%20and%20Clinical%20Psychosis%20Care%20https%3A%2F%2Fcedclinic.com%2Fclinical-psychosis-care-endocannabinoid-system-research%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).